Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Harris A Ahmad
  • Joshua F Baker
  • Mikkel Østergaard
  • Paul Emery
  • Patrick Durez
  • June Ye
  • Subhashis Banerjee
  • Philip G Conaghan
View graph of relations

OBJECTIVE: High magnetic resonance imaging (MRI)-detected inflammation is associated with greater progression and poorer outcomes in rheumatoid arthritis (RA). This analysis aimed to determine if baseline MRI inflammation was related to clinical response and remission in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study.

METHODS: AVERT was a phase IIIb, randomized, controlled trial with a 12-month, double-blind treatment period enrolling patients with early (≤2 years' duration), anti-citrullinated peptide-positive methotrexate (MTX)-naive RA. In this post hoc analysis, patients in the abatacept plus MTX (n = 114) and MTX (n = 111) arms with available MRI results were stratified into low and high baseline MRI inflammation groups based on previously developed cutoffs of synovitis and osteitis on unilateral hand-wrist contrast-enhanced MRI. Simplified Disease Activity Index (SDAI) remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity Score in 28 joints using the C-reactive protein level (<2.6) were assessed.

RESULTS: Overall, 100 of 225 patients (44.4%) had high baseline MRI inflammation. In patients with high baseline MRI inflammation, a significantly greater proportion achieved remission at 12 months with abatacept plus MTX versus MTX across SDAI (45.1% versus 16.3%; P = 0.0022), CDAI (47.1% versus 20.4%; P = 0.0065), and Boolean indices (39.2% versus 16.3%; P = 0.0156). In patients with low baseline MRI inflammation, remission rates were not significantly different with abatacept plus MTX versus MTX (SDAI: 39.7% versus 32.3%; P = 0.4961).

CONCLUSION: In seropositive, MTX-naive patients with early RA and presence of objectively measured high inflammation by MRI, indicating poor prognosis, remission rates were higher with abatacept plus MTX treatment versus MTX.

Original languageEnglish
JournalArthritis Care & Research
Issue number7
Pages (from-to)959-964
Number of pages6
Publication statusPublished - Jul 2020

Bibliographical note

© 2019 The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

ID: 58908348